+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Passive Immunizing Drugs against Rabies Market by Product Type (Formulation), Application (Postexposure Prophylaxis, Preexposure Prophylaxis), Distribution Channel, End User, Route Of Administration - Global Forecast 2025-2030- Product Image
Passive Immunizing Drugs against Rabies Market by Product Type (Formulation), Application (Postexposure Prophylaxis, Preexposure Prophylaxis), Distribution Channel, End User, Route Of Administration - Global Forecast 2025-2030- Product Image
New

Passive Immunizing Drugs against Rabies Market by Product Type (Formulation), Application (Postexposure Prophylaxis, Preexposure Prophylaxis), Distribution Channel, End User, Route Of Administration - Global Forecast 2025-2030

  • PDF Icon

    Report

  • 197 Pages
  • August 2025
  • Region: Global
  • 360iResearch™
  • ID: 6134348
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

Unveiling the Imperative of Passive Immunizing Agents Against Rabies: A Foundation for In-Depth Market Analysis and Strategic Decision-Making

The persistent danger of rabies transmission continues to challenge global health systems, underscoring the indispensable role of passive immunizing drugs. These therapeutic agents, comprised of ready-to-use antibodies, bridge the critical time window between potential exposure and the establishment of active immunity. In regions burdened by high rates of animal-to-human transmission, the availability and strategic deployment of passive immunotherapeutics represent a vital safeguard against the progression of fatal infections.

Against this backdrop, a clear understanding of market dynamics and therapeutic innovations is essential for stakeholders including pharmaceutical developers, public health authorities, and clinical practitioners. By examining the scientific foundations and commercialization pathways of passive immunizing agents, this executive summary lays the groundwork for informed decision-making. It highlights the therapeutic rationale, explores the interplay of research and regulation, and frames the market landscape in terms of evolving needs and technological advancements. As such, this section establishes the context for a deeper exploration of the shifts, impacts, and opportunities shaping the future of rabies prophylaxis through passive immunization strategies.

Embracing Biotechnological Breakthroughs and Strategic Therapeutic Innovations Reshaping the Future of Passive Immunizing Drugs for Rabies Prevention

Rapid advancements in biotechnology have ushered in a new era for passive immunizing drugs targeting rabies, marked by the advent of monoclonal and polyclonal antibody platforms that deliver enhanced safety profiles and manufacturing predictability. As a result, research labs and commercial developers are prioritizing novel antibody engineering techniques, leveraging recombinant DNA technologies to optimize specificity and potency. Furthermore, the integration of high-throughput screening methods has accelerated the identification of lead candidates with broad neutralizing capacity against diverse rabies strains.

Concurrently, strategic partnerships between academic institutions, contract manufacturing organizations, and global health agencies have emerged as powerful catalysts for scaling up production and broadening geographic reach. Market participants are progressively adopting continuous bioprocessing frameworks, which reduce production costs and improve batch consistency. In parallel, regulatory bodies have begun to refine approval pathways for novel antibody therapeutics, fostering a more predictable path to market. Taken together, these transformative shifts are redefining the landscape of passive rabies immunization by enabling faster development cycles, more robust supply chains, and ultimately enhanced access for at-risk populations.

Assessing the Ripple Effects of United States Tariff Revisions on the Supply Chain and Commercial Dynamics of Passive Immunizing Anti-Rabies Therapies

The introduction of revised tariff schedules by the United States in 2025 has introduced new complexity into the supply chain economics of passive immunizing therapies against rabies. Import duties on key raw materials and critical reagents have elevated production expenses, prompting manufacturers to reevaluate sourcing strategies and negotiate bulk procurement contracts. Moreover, heightened costs in international logistics have impacted lead times, necessitating refined inventory management practices to cushion against potential stockouts in high-incidence regions.

Despite these headwinds, forward-thinking companies have responded by diversifying their supply networks and seeking alternative regional partners to mitigate the impact of import levies. In parallel, some producers are exploring vertical integration models to internalize reagent manufacturing and reduce exposure to external cost fluctuations. At the same time, strategic alliances with domestic contract manufacturers have enabled continuity of supply while navigating evolving trade policies. On balance, the combined effect of U.S. tariffs in 2025 has reinforced the imperative for flexible sourcing, resilient production footprints, and adaptive pricing frameworks to sustain the delivery of passive immunizing anti-rabies drugs.

Decoding Critical Market Segmentation Dimensions from Formulation Through Administration to Uncover Actionable Insights for Passive Rabies Immunotherapies

A nuanced segmentation approach reveals distinct market dynamics and opportunities across multiple dimensions. Analysis based on product type highlights the contrasting demand patterns for liquid form formulations, favored for immediate administration, and lyophilized form presentations, valued for extended shelf life and ease of transport. When viewed through the lens of application, the market splits between postexposure prophylaxis, driving urgent usage scenarios, and preexposure prophylaxis, which underpins preventative strategies in high-risk cohorts.

Distribution channel segmentation underscores the evolving roles of hospital pharmacies as primary procurement hubs, online pharmacies catering to remote or resource-constrained environments, and retail pharmacies offering consumer-facing access points. Meanwhile, end user segmentation illuminates the differential utilization in clinics, which focus on rapid response, versus hospitals, which integrate comprehensive care protocols, and research institutes, where experimental and diagnostic applications prevail. Additionally, route of administration distinctions between intramuscular injection, intravenous injection and wound infiltration elucidate procedural requirements, training considerations, and patient compliance factors that shape protocol selection and service delivery models.

Examining Regional Variances in Access, Adoption and Regulatory Frameworks Across the Americas Europe Middle East and Africa and Asia-Pacific Markets

Geographic analysis of passive immunizing drugs against rabies reveals pronounced regional contrasts in regulatory frameworks, healthcare infrastructure, and disease prevalence. In the Americas, established distribution channels and strong public health initiatives have balanced demand between postexposure and preexposure prophylaxis use cases, while manufacturers explore localized production hubs to streamline supply. Shifting westward, stakeholder collaboration continues to fortify distribution networks, particularly within underserved rural communities.

Within Europe Middle East and Africa, regulatory harmonization efforts are accelerating approval timelines for advanced antibody therapeutics, though variable healthcare spending priorities create pockets of both robust uptake and unmet need. Multilateral partnerships and philanthropic funding play a critical role in expanding access to passive immunization solutions. In the Asia-Pacific sphere, surging urbanization and rising awareness of zoonotic disease risks have spurred government-driven prophylactic campaigns. High-volume healthcare settings in this region favor liquid formulation adoption, supported by continuous bioprocessing investments that enhance local manufacturing capabilities. Collectively, these regional insights inform targeted strategic planning for market entrants and established players alike.

Highlighting Strategic Collaborations and Competitive Positioning of Leading Pharmaceutical and Biotechnology Corporations Driving Passive Rabies Immunizing Drug Development

Leading pharmaceutical and biotechnology firms are intensifying their focus on passive immunizing therapies for rabies through strategic collaborations, licensing agreements and targeted research initiatives. Global conglomerates are leveraging their extensive manufacturing footprints to scale up production of monoclonal antibody candidates, while emerging biotech specialists concentrate on innovative delivery technologies that enhance stability and reduce cold chain dependency. Additionally, several players are investing in next-generation platforms capable of producing broadly neutralizing antibody cocktails, addressing the diversity of circulating rabies virus strains.

To strengthen their competitive positioning, companies are forging partnerships with contract development and manufacturing organizations that possess specialized expertise in antibody purification and formulation. Venture-backed startups are attracting capital through promising clinical data, driving accelerated timelines toward regulatory milestones. At the same time, integration of artificial intelligence in antibody design and process optimization has begun to differentiate high-potential pipelines from more traditional biologics programs. As market participants navigate this evolving landscape, the combination of scale, technological sophistication and strategic alliances is emerging as the defining characteristic of industry leadership in passive rabies immunization.

Empowering Industry Stakeholders with Pragmatic Strategies to Accelerate Market Entry Optimize Portfolios and Leverage Emerging Opportunities in Passive Rabies Immunization

To capture the full potential of passive immunizing therapies in the fight against rabies, industry stakeholders must adopt a series of proactive strategies. Organizations aiming to accelerate market entry should invest in end-to-end supply chain flexibility, integrating multiple contract manufacturers to safeguard against geopolitical or trade-related disruptions. Equally important is the alignment of clinical development plans with evolving regulatory expectations, thereby streamlining approval pathways and reducing time to market.

Additionally, commercial teams should prioritize data-driven outreach programs that articulate the unique value proposition of both liquid and lyophilized antibody formulations, tailoring messaging to hospital, clinic and online pharmacy audiences. Research collaborations with academic and public health institutions can yield critical real-world evidence to support adoption in regions with high disease incidence. Finally, leaders are encouraged to explore strategic licensing or joint venture opportunities to expand regional manufacturing coverage, optimize capital allocation and establish a resilient global footprint capable of meeting both routine prophylactic and emergency response demands.

Detailing a Rigorous Multi-Faceted Research Methodology Incorporating Primary Interviews Secondary Data Analysis and Expert Validation for Credible Insights

This research initiative combined a rigorous multi-phase methodology to ensure the integrity and relevance of findings. Primary data collection involved structured interviews with industry executives, regulatory experts and field epidemiologists, providing firsthand insights into production challenges, adoption barriers and future innovation trajectories. Simultaneously, secondary research drew upon peer-reviewed journals, patent filings and public agency guidelines to contextualize emerging scientific developments within the broader competitive landscape.

Data triangulation techniques were employed to validate qualitative inputs against quantitative performance indicators, while sensitivity analyses tested the robustness of segmentation parameters. Expert panels convened throughout the study to critique preliminary conclusions, enabling iterative refinement of strategic themes and regional projections. This layered approach ensures that the resulting market intelligence is actionable, transparent and aligned with the highest standards of analytical rigor.

Concluding Insights Emphasizing Strategic Imperatives and Forward-Looking Perspectives for Sustained Growth in Passive Immunizing Treatments Against Rabies

The future of passive immunizing drugs against rabies hinges on the confluence of cutting-edge science, adaptive supply chain models and collaborative frameworks that bridge public and private spheres. As monoclonal antibody technologies mature and regulatory pathways become more predictable, market participants will find new avenues to enhance both prophylactic programs and emergency response protocols. Regional insights reinforce the need for customized strategies, whether optimizing cold chain logistics in emerging markets or leveraging advanced formulation platforms in established healthcare systems.

Ultimately, successful navigation of this dynamic environment requires an integrated perspective-one that synthesizes segmentation intelligence, tariff impact assessments and competitive benchmarks into a cohesive strategic roadmap. Stakeholders who embrace data-driven decision making, invest in strategic partnerships, and maintain agility in manufacturing and distribution practices are best positioned to deliver life-saving therapies and sustain long-term growth. This report offers the essential insights needed to inform those decisions and shape the trajectory of passive rabies immunization efforts worldwide.

Market Segmentation & Coverage

This research report categorizes to forecast the revenues and analyze trends in each of the following sub-segmentations:
  • Product Type
    • Formulation
      • Liquid Form
      • Lyophilized Form
  • Application
    • Postexposure Prophylaxis
    • Preexposure Prophylaxis
  • Distribution Channel
    • Hospital Pharmacy
    • Online Pharmacy
    • Retail Pharmacy
  • End User
    • Clinics
    • Hospitals
    • Research Institutes
  • Route Of Administration
    • Intramuscular Injection
    • Intravenous Injection
    • Wound Infiltration
This research report categorizes to forecast the revenues and analyze trends in each of the following sub-regions:
  • Americas
    • United States
      • California
      • Texas
      • New York
      • Florida
      • Illinois
      • Pennsylvania
      • Ohio
    • Canada
    • Mexico
    • Brazil
    • Argentina
  • Europe, Middle East & Africa
    • United Kingdom
    • Germany
    • France
    • Russia
    • Italy
    • Spain
    • United Arab Emirates
    • Saudi Arabia
    • South Africa
    • Denmark
    • Netherlands
    • Qatar
    • Finland
    • Sweden
    • Nigeria
    • Egypt
    • Turkey
    • Israel
    • Norway
    • Poland
    • Switzerland
  • Asia-Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
    • Indonesia
    • Thailand
    • Philippines
    • Malaysia
    • Singapore
    • Vietnam
    • Taiwan
This research report delves into recent significant developments and analyzes trends in each of the following companies:
  • Grifols S.A.
  • Takeda Pharmaceutical Company Limited
  • CSL Limited
  • Octapharma AG
  • Kedrion S.p.A.
  • Serum Institute of India Private Limited
  • Les Laboratoires Français du Fractionnement et des Biotechnologies (LFB)
  • Shandong Taibang Biopharmaceutical Co., Ltd.
  • Tianjin Kinghem Pharmaceutical Co., Ltd.
  • Haffkine Bio-Pharmaceutical Corporation Limited

This product will be delivered within 1-3 business days.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary
4. Market Overview
4.1. Introduction
4.2. Market Sizing & Forecasting
5. Market Dynamics
5.1. Rapid adoption of monoclonal antibody therapies to replace traditional rabies immunoglobulins
5.2. Emergence of extended half-life antibody engineering enhancing post-exposure prophylaxis efficacy
5.3. Implementation of intradermal administration protocols to optimize limited rabies immunoglobulin supplies
5.4. Strategic partnerships between local manufacturers and global biotech firms improving RIG production capacity
5.5. Regulatory approvals of novel fully human rabies mAbs driving market diversification in Asia Pacific
5.6. Cost reduction initiatives through recombinant antibody platforms reducing manufacturing expenses
5.7. Deployment of mobile serum fractionation units to strengthen rabies immunoglobulin availability in remote areas
5.8. Innovations in lyophilized RIG formulations to enhance cold chain independence in tropical regions
6. Market Insights
6.1. Porter’s Five Forces Analysis
6.2. PESTLE Analysis
7. Cumulative Impact of United States Tariffs 2025
8. Passive Immunizing Drugs against Rabies Market, by Product Type
8.1. Introduction
8.2. Formulation
8.2.1. Liquid Form
8.2.2. Lyophilized Form
9. Passive Immunizing Drugs against Rabies Market, by Application
9.1. Introduction
9.2. Postexposure Prophylaxis
9.3. Preexposure Prophylaxis
10. Passive Immunizing Drugs against Rabies Market, by Distribution Channel
10.1. Introduction
10.2. Hospital Pharmacy
10.3. Online Pharmacy
10.4. Retail Pharmacy
11. Passive Immunizing Drugs against Rabies Market, by End User
11.1. Introduction
11.2. Clinics
11.3. Hospitals
11.4. Research Institutes
12. Passive Immunizing Drugs against Rabies Market, by Route Of Administration
12.1. Introduction
12.2. Intramuscular Injection
12.3. Intravenous Injection
12.4. Wound Infiltration
13. Americas Passive Immunizing Drugs against Rabies Market
13.1. Introduction
13.2. United States
13.3. Canada
13.4. Mexico
13.5. Brazil
13.6. Argentina
14. Europe, Middle East & Africa Passive Immunizing Drugs against Rabies Market
14.1. Introduction
14.2. United Kingdom
14.3. Germany
14.4. France
14.5. Russia
14.6. Italy
14.7. Spain
14.8. United Arab Emirates
14.9. Saudi Arabia
14.10. South Africa
14.11. Denmark
14.12. Netherlands
14.13. Qatar
14.14. Finland
14.15. Sweden
14.16. Nigeria
14.17. Egypt
14.18. Turkey
14.19. Israel
14.20. Norway
14.21. Poland
14.22. Switzerland
15. Asia-Pacific Passive Immunizing Drugs against Rabies Market
15.1. Introduction
15.2. China
15.3. India
15.4. Japan
15.5. Australia
15.6. South Korea
15.7. Indonesia
15.8. Thailand
15.9. Philippines
15.10. Malaysia
15.11. Singapore
15.12. Vietnam
15.13. Taiwan
16. Competitive Landscape
16.1. Market Share Analysis, 2024
16.2. FPNV Positioning Matrix, 2024
16.3. Competitive Analysis
16.3.1. Grifols S.A.
16.3.2. Takeda Pharmaceutical Company Limited
16.3.3. CSL Limited
16.3.4. Octapharma AG
16.3.5. Kedrion S.p.A.
16.3.6. Serum Institute of India Private Limited
16.3.7. Les Laboratoires Français du Fractionnement et des Biotechnologies (LFB)
16.3.8. Shandong Taibang Biopharmaceutical Co., Ltd.
16.3.9. Tianjin Kinghem Pharmaceutical Co., Ltd.
16.3.10. Haffkine Bio-Pharmaceutical Corporation Limited
17. ResearchAI18. ResearchStatistics19. ResearchContacts20. ResearchArticles21. Appendix
List of Figures
FIGURE 1. PASSIVE IMMUNIZING DRUGS AGAINST RABIES MARKET RESEARCH PROCESS
FIGURE 2. GLOBAL PASSIVE IMMUNIZING DRUGS AGAINST RABIES MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 3. GLOBAL PASSIVE IMMUNIZING DRUGS AGAINST RABIES MARKET SIZE, BY REGION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 4. GLOBAL PASSIVE IMMUNIZING DRUGS AGAINST RABIES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 5. GLOBAL PASSIVE IMMUNIZING DRUGS AGAINST RABIES MARKET SIZE, BY PRODUCT TYPE, 2024 VS 2030 (%)
FIGURE 6. GLOBAL PASSIVE IMMUNIZING DRUGS AGAINST RABIES MARKET SIZE, BY PRODUCT TYPE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 7. GLOBAL PASSIVE IMMUNIZING DRUGS AGAINST RABIES MARKET SIZE, BY APPLICATION, 2024 VS 2030 (%)
FIGURE 8. GLOBAL PASSIVE IMMUNIZING DRUGS AGAINST RABIES MARKET SIZE, BY APPLICATION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 9. GLOBAL PASSIVE IMMUNIZING DRUGS AGAINST RABIES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2030 (%)
FIGURE 10. GLOBAL PASSIVE IMMUNIZING DRUGS AGAINST RABIES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 11. GLOBAL PASSIVE IMMUNIZING DRUGS AGAINST RABIES MARKET SIZE, BY END USER, 2024 VS 2030 (%)
FIGURE 12. GLOBAL PASSIVE IMMUNIZING DRUGS AGAINST RABIES MARKET SIZE, BY END USER, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 13. GLOBAL PASSIVE IMMUNIZING DRUGS AGAINST RABIES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2030 (%)
FIGURE 14. GLOBAL PASSIVE IMMUNIZING DRUGS AGAINST RABIES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 15. AMERICAS PASSIVE IMMUNIZING DRUGS AGAINST RABIES MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 16. AMERICAS PASSIVE IMMUNIZING DRUGS AGAINST RABIES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 17. UNITED STATES PASSIVE IMMUNIZING DRUGS AGAINST RABIES MARKET SIZE, BY STATE, 2024 VS 2030 (%)
FIGURE 18. UNITED STATES PASSIVE IMMUNIZING DRUGS AGAINST RABIES MARKET SIZE, BY STATE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 19. EUROPE, MIDDLE EAST & AFRICA PASSIVE IMMUNIZING DRUGS AGAINST RABIES MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 20. EUROPE, MIDDLE EAST & AFRICA PASSIVE IMMUNIZING DRUGS AGAINST RABIES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 21. ASIA-PACIFIC PASSIVE IMMUNIZING DRUGS AGAINST RABIES MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 22. ASIA-PACIFIC PASSIVE IMMUNIZING DRUGS AGAINST RABIES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 23. PASSIVE IMMUNIZING DRUGS AGAINST RABIES MARKET SHARE, BY KEY PLAYER, 2024
FIGURE 24. PASSIVE IMMUNIZING DRUGS AGAINST RABIES MARKET, FPNV POSITIONING MATRIX, 2024
FIGURE 25. PASSIVE IMMUNIZING DRUGS AGAINST RABIES MARKET: RESEARCHAI
FIGURE 26. PASSIVE IMMUNIZING DRUGS AGAINST RABIES MARKET: RESEARCHSTATISTICS
FIGURE 27. PASSIVE IMMUNIZING DRUGS AGAINST RABIES MARKET: RESEARCHCONTACTS
FIGURE 28. PASSIVE IMMUNIZING DRUGS AGAINST RABIES MARKET: RESEARCHARTICLES
List of Tables
TABLE 1. PASSIVE IMMUNIZING DRUGS AGAINST RABIES MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
TABLE 3. GLOBAL PASSIVE IMMUNIZING DRUGS AGAINST RABIES MARKET SIZE, 2018-2024 (USD MILLION)
TABLE 4. GLOBAL PASSIVE IMMUNIZING DRUGS AGAINST RABIES MARKET SIZE, 2025-2030 (USD MILLION)
TABLE 5. GLOBAL PASSIVE IMMUNIZING DRUGS AGAINST RABIES MARKET SIZE, BY REGION, 2018-2024 (USD MILLION)
TABLE 6. GLOBAL PASSIVE IMMUNIZING DRUGS AGAINST RABIES MARKET SIZE, BY REGION, 2025-2030 (USD MILLION)
TABLE 7. GLOBAL PASSIVE IMMUNIZING DRUGS AGAINST RABIES MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
TABLE 8. GLOBAL PASSIVE IMMUNIZING DRUGS AGAINST RABIES MARKET SIZE, BY COUNTRY, 2025-2030 (USD MILLION)
TABLE 9. GLOBAL PASSIVE IMMUNIZING DRUGS AGAINST RABIES MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
TABLE 10. GLOBAL PASSIVE IMMUNIZING DRUGS AGAINST RABIES MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
TABLE 11. GLOBAL PASSIVE IMMUNIZING DRUGS AGAINST RABIES MARKET SIZE, BY FORMULATION, BY REGION, 2018-2024 (USD MILLION)
TABLE 12. GLOBAL PASSIVE IMMUNIZING DRUGS AGAINST RABIES MARKET SIZE, BY FORMULATION, BY REGION, 2025-2030 (USD MILLION)
TABLE 13. GLOBAL PASSIVE IMMUNIZING DRUGS AGAINST RABIES MARKET SIZE, BY LIQUID FORM, BY REGION, 2018-2024 (USD MILLION)
TABLE 14. GLOBAL PASSIVE IMMUNIZING DRUGS AGAINST RABIES MARKET SIZE, BY LIQUID FORM, BY REGION, 2025-2030 (USD MILLION)
TABLE 15. GLOBAL PASSIVE IMMUNIZING DRUGS AGAINST RABIES MARKET SIZE, BY LYOPHILIZED FORM, BY REGION, 2018-2024 (USD MILLION)
TABLE 16. GLOBAL PASSIVE IMMUNIZING DRUGS AGAINST RABIES MARKET SIZE, BY LYOPHILIZED FORM, BY REGION, 2025-2030 (USD MILLION)
TABLE 17. GLOBAL PASSIVE IMMUNIZING DRUGS AGAINST RABIES MARKET SIZE, BY FORMULATION, 2018-2024 (USD MILLION)
TABLE 18. GLOBAL PASSIVE IMMUNIZING DRUGS AGAINST RABIES MARKET SIZE, BY FORMULATION, 2025-2030 (USD MILLION)
TABLE 19. GLOBAL PASSIVE IMMUNIZING DRUGS AGAINST RABIES MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
TABLE 20. GLOBAL PASSIVE IMMUNIZING DRUGS AGAINST RABIES MARKET SIZE, BY APPLICATION, 2025-2030 (USD MILLION)
TABLE 21. GLOBAL PASSIVE IMMUNIZING DRUGS AGAINST RABIES MARKET SIZE, BY POSTEXPOSURE PROPHYLAXIS, BY REGION, 2018-2024 (USD MILLION)
TABLE 22. GLOBAL PASSIVE IMMUNIZING DRUGS AGAINST RABIES MARKET SIZE, BY POSTEXPOSURE PROPHYLAXIS, BY REGION, 2025-2030 (USD MILLION)
TABLE 23. GLOBAL PASSIVE IMMUNIZING DRUGS AGAINST RABIES MARKET SIZE, BY PREEXPOSURE PROPHYLAXIS, BY REGION, 2018-2024 (USD MILLION)
TABLE 24. GLOBAL PASSIVE IMMUNIZING DRUGS AGAINST RABIES MARKET SIZE, BY PREEXPOSURE PROPHYLAXIS, BY REGION, 2025-2030 (USD MILLION)
TABLE 25. GLOBAL PASSIVE IMMUNIZING DRUGS AGAINST RABIES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 26. GLOBAL PASSIVE IMMUNIZING DRUGS AGAINST RABIES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 27. GLOBAL PASSIVE IMMUNIZING DRUGS AGAINST RABIES MARKET SIZE, BY HOSPITAL PHARMACY, BY REGION, 2018-2024 (USD MILLION)
TABLE 28. GLOBAL PASSIVE IMMUNIZING DRUGS AGAINST RABIES MARKET SIZE, BY HOSPITAL PHARMACY, BY REGION, 2025-2030 (USD MILLION)
TABLE 29. GLOBAL PASSIVE IMMUNIZING DRUGS AGAINST RABIES MARKET SIZE, BY ONLINE PHARMACY, BY REGION, 2018-2024 (USD MILLION)
TABLE 30. GLOBAL PASSIVE IMMUNIZING DRUGS AGAINST RABIES MARKET SIZE, BY ONLINE PHARMACY, BY REGION, 2025-2030 (USD MILLION)
TABLE 31. GLOBAL PASSIVE IMMUNIZING DRUGS AGAINST RABIES MARKET SIZE, BY RETAIL PHARMACY, BY REGION, 2018-2024 (USD MILLION)
TABLE 32. GLOBAL PASSIVE IMMUNIZING DRUGS AGAINST RABIES MARKET SIZE, BY RETAIL PHARMACY, BY REGION, 2025-2030 (USD MILLION)
TABLE 33. GLOBAL PASSIVE IMMUNIZING DRUGS AGAINST RABIES MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 34. GLOBAL PASSIVE IMMUNIZING DRUGS AGAINST RABIES MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 35. GLOBAL PASSIVE IMMUNIZING DRUGS AGAINST RABIES MARKET SIZE, BY CLINICS, BY REGION, 2018-2024 (USD MILLION)
TABLE 36. GLOBAL PASSIVE IMMUNIZING DRUGS AGAINST RABIES MARKET SIZE, BY CLINICS, BY REGION, 2025-2030 (USD MILLION)
TABLE 37. GLOBAL PASSIVE IMMUNIZING DRUGS AGAINST RABIES MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2024 (USD MILLION)
TABLE 38. GLOBAL PASSIVE IMMUNIZING DRUGS AGAINST RABIES MARKET SIZE, BY HOSPITALS, BY REGION, 2025-2030 (USD MILLION)
TABLE 39. GLOBAL PASSIVE IMMUNIZING DRUGS AGAINST RABIES MARKET SIZE, BY RESEARCH INSTITUTES, BY REGION, 2018-2024 (USD MILLION)
TABLE 40. GLOBAL PASSIVE IMMUNIZING DRUGS AGAINST RABIES MARKET SIZE, BY RESEARCH INSTITUTES, BY REGION, 2025-2030 (USD MILLION)
TABLE 41. GLOBAL PASSIVE IMMUNIZING DRUGS AGAINST RABIES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 42. GLOBAL PASSIVE IMMUNIZING DRUGS AGAINST RABIES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 43. GLOBAL PASSIVE IMMUNIZING DRUGS AGAINST RABIES MARKET SIZE, BY INTRAMUSCULAR INJECTION, BY REGION, 2018-2024 (USD MILLION)
TABLE 44. GLOBAL PASSIVE IMMUNIZING DRUGS AGAINST RABIES MARKET SIZE, BY INTRAMUSCULAR INJECTION, BY REGION, 2025-2030 (USD MILLION)
TABLE 45. GLOBAL PASSIVE IMMUNIZING DRUGS AGAINST RABIES MARKET SIZE, BY INTRAVENOUS INJECTION, BY REGION, 2018-2024 (USD MILLION)
TABLE 46. GLOBAL PASSIVE IMMUNIZING DRUGS AGAINST RABIES MARKET SIZE, BY INTRAVENOUS INJECTION, BY REGION, 2025-2030 (USD MILLION)
TABLE 47. GLOBAL PASSIVE IMMUNIZING DRUGS AGAINST RABIES MARKET SIZE, BY WOUND INFILTRATION, BY REGION, 2018-2024 (USD MILLION)
TABLE 48. GLOBAL PASSIVE IMMUNIZING DRUGS AGAINST RABIES MARKET SIZE, BY WOUND INFILTRATION, BY REGION, 2025-2030 (USD MILLION)
TABLE 49. AMERICAS PASSIVE IMMUNIZING DRUGS AGAINST RABIES MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
TABLE 50. AMERICAS PASSIVE IMMUNIZING DRUGS AGAINST RABIES MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
TABLE 51. AMERICAS PASSIVE IMMUNIZING DRUGS AGAINST RABIES MARKET SIZE, BY FORMULATION, 2018-2024 (USD MILLION)
TABLE 52. AMERICAS PASSIVE IMMUNIZING DRUGS AGAINST RABIES MARKET SIZE, BY FORMULATION, 2025-2030 (USD MILLION)
TABLE 53. AMERICAS PASSIVE IMMUNIZING DRUGS AGAINST RABIES MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
TABLE 54. AMERICAS PASSIVE IMMUNIZING DRUGS AGAINST RABIES MARKET SIZE, BY APPLICATION, 2025-2030 (USD MILLION)
TABLE 55. AMERICAS PASSIVE IMMUNIZING DRUGS AGAINST RABIES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 56. AMERICAS PASSIVE IMMUNIZING DRUGS AGAINST RABIES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 57. AMERICAS PASSIVE IMMUNIZING DRUGS AGAINST RABIES MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 58. AMERICAS PASSIVE IMMUNIZING DRUGS AGAINST RABIES MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 59. AMERICAS PASSIVE IMMUNIZING DRUGS AGAINST RABIES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 60. AMERICAS PASSIVE IMMUNIZING DRUGS AGAINST RABIES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 61. AMERICAS PASSIVE IMMUNIZING DRUGS AGAINST RABIES MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
TABLE 62. AMERICAS PASSIVE IMMUNIZING DRUGS AGAINST RABIES MARKET SIZE, BY COUNTRY, 2025-2030 (USD MILLION)
TABLE 63. UNITED STATES PASSIVE IMMUNIZING DRUGS AGAINST RABIES MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
TABLE 64. UNITED STATES PASSIVE IMMUNIZING DRUGS AGAINST RABIES MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
TABLE 65. UNITED STATES PASSIVE IMMUNIZING DRUGS AGAINST RABIES MARKET SIZE, BY FORMULATION, 2018-2024 (USD MILLION)
TABLE 66. UNITED STATES PASSIVE IMMUNIZING DRUGS AGAINST RABIES MARKET SIZE, BY FORMULATION, 2025-2030 (USD MILLION)
TABLE 67. UNITED STATES PASSIVE IMMUNIZING DRUGS AGAINST RABIES MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
TABLE 68. UNITED STATES PASSIVE IMMUNIZING DRUGS AGAINST RABIES MARKET SIZE, BY APPLICATION, 2025-2030 (USD MILLION)
TABLE 69. UNITED STATES PASSIVE IMMUNIZING DRUGS AGAINST RABIES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 70. UNITED STATES PASSIVE IMMUNIZING DRUGS AGAINST RABIES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 71. UNITED STATES PASSIVE IMMUNIZING DRUGS AGAINST RABIES MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 72. UNITED STATES PASSIVE IMMUNIZING DRUGS AGAINST RABIES MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 73. UNITED STATES PASSIVE IMMUNIZING DRUGS AGAINST RABIES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 74. UNITED STATES PASSIVE IMMUNIZING DRUGS AGAINST RABIES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 75. UNITED STATES PASSIVE IMMUNIZING DRUGS AGAINST RABIES MARKET SIZE, BY STATE, 2018-2024 (USD MILLION)
TABLE 76. UNITED STATES PASSIVE IMMUNIZING DRUGS AGAINST RABIES MARKET SIZE, BY STATE, 2025-2030 (USD MILLION)
TABLE 77. CANADA PASSIVE IMMUNIZING DRUGS AGAINST RABIES MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
TABLE 78. CANADA PASSIVE IMMUNIZING DRUGS AGAINST RABIES MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
TABLE 79. CANADA PASSIVE IMMUNIZING DRUGS AGAINST RABIES MARKET SIZE, BY FORMULATION, 2018-2024 (USD MILLION)
TABLE 80. CANADA PASSIVE IMMUNIZING DRUGS AGAINST RABIES MARKET SIZE, BY FORMULATION, 2025-2030 (USD MILLION)
TABLE 81. CANADA PASSIVE IMMUNIZING DRUGS AGAINST RABIES MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
TABLE 82. CANADA PASSIVE IMMUNIZING DRUGS AGAINST RABIES MARKET SIZE, BY APPLICATION, 2025-2030 (USD MILLION)
TABLE 83. CANADA PASSIVE IMMUNIZING DRUGS AGAINST RABIES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 84. CANADA PASSIVE IMMUNIZING DRUGS AGAINST RABIES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 85. CANADA PASSIVE IMMUNIZING DRUGS AGAINST RABIES MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 86. CANADA PASSIVE IMMUNIZING DRUGS AGAINST RABIES MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 87. CANADA PASSIVE IMMUNIZING DRUGS AGAINST RABIES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 88. CANADA PASSIVE IMMUNIZING DRUGS AGAINST RABIES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 89. MEXICO PASSIVE IMMUNIZING DRUGS AGAINST RABIES MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
TABLE 90. MEXICO PASSIVE IMMUNIZING DRUGS AGAINST RABIES MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
TABLE 91. MEXICO PASSIVE IMMUNIZING DRUGS AGAINST RABIES MARKET SIZE, BY FORMULATION, 2018-2024 (USD MILLION)
TABLE 92. MEXICO PASSIVE IMMUNIZING DRUGS AGAINST RABIES MARKET SIZE, BY FORMULATION, 2025-2030 (USD MILLION)
TABLE 93. MEXICO PASSIVE IMMUNIZING DRUGS AGAINST RABIES MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
TABLE 94. MEXICO PASSIVE IMMUNIZING DRUGS AGAINST RABIES MARKET SIZE, BY APPLICATION, 2025-2030 (USD MILLION)
TABLE 95. MEXICO PASSIVE IMMUNIZING DRUGS AGAINST RABIES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 96. MEXICO PASSIVE IMMUNIZING DRUGS AGAINST RABIES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 97. MEXICO PASSIVE IMMUNIZING DRUGS AGAINST RABIES MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 98. MEXICO PASSIVE IMMUNIZING DRUGS AGAINST RABIES MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 99. MEXICO PASSIVE IMMUNIZING DRUGS AGAINST RABIES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 100. MEXICO PASSIVE IMMUNIZING DRUGS AGAINST RABIES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 101. BRAZIL PASSIVE IMMUNIZING DRUGS AGAINST RABIES MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
TABLE 102. BRAZIL PASSIVE IMMUNIZING DRUGS AGAINST RABIES MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
TABLE 103. BRAZIL PASSIVE IMMUNIZING DRUGS AGAINST RABIES MARKET SIZE, BY FORMULATION, 2018-2024 (USD MILLION)
TABLE 104. BRAZIL PASSIVE IMMUNIZING DRUGS AGAINST RABIES MARKET SIZE, BY FORMULATION, 2025-2030 (USD MILLION)
TABLE 105. BRAZIL PASSIVE IMMUNIZING DRUGS AGAINST RABIES MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
TABLE 106. BRAZIL PASSIVE IMMUNIZING DRUGS AGAINST RABIES MARKET SIZE, BY APPLICATION, 2025-2030 (USD MILLION)
TABLE 107. BRAZIL PASSIVE IMMUNIZING DRUGS AGAINST RABIES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 108. BRAZIL PASSIVE IMMUNIZING DRUGS AGAINST RABIES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 109. BRAZIL PASSIVE IMMUNIZING DRUGS AGAINST RABIES MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 110. BRAZIL PASSIVE IMMUNIZING DRUGS AGAINST RABIES MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 111. BRAZIL PASSIVE IMMUNIZING DRUGS AGAINST RABIES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 112. BRAZIL PASSIVE IMMUNIZING DRUGS AGAINST RABIES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 113. ARGENTINA PASSIVE IMMUNIZING DRUGS AGAINST RABIES MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
TABLE 114. ARGENTINA PASSIVE IMMUNIZING DRUGS AGAINST RABIES MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
TABLE 115. ARGENTINA PASSIVE IMMUNIZING DRUGS AGAINST RABIES MARKET SIZE, BY FORMULATION, 2018-2024 (USD MILLION)
TABLE 116. ARGENTINA PASSIVE IMMUNIZING DRUGS AGAINST RABIES MARKET SIZE, BY FORMULATION, 2025-2030 (USD MILLION)
TABLE 117. ARGENTINA PASSIVE IMMUNIZING DRUGS AGAINST RABIES MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
TABLE 118. ARGENTINA PASSIVE IMMUNIZING DRUGS AGAINST RABIES MARKET SIZE, BY APPLICATION, 2025-2030 (USD MILLION)
TABLE 119. ARGENTINA PASSIVE IMMUNIZING DRUGS AGAINST RABIES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 120. ARGENTINA PASSIVE IMMUNIZING DRUGS AGAINST RABIES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 121. ARGENTINA PASSIVE IMMUNIZING DRUGS AGAINST RABIES MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 122. ARGENTINA PASSIVE IMMUNIZING DRUGS AGAINST RABIES MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 123. ARGENTINA PASSIVE IMMUNIZING DRUGS AGAINST RABIES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 124. ARGENTINA PASSIVE IMMUNIZING DRUGS AGAINST RABIES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 125. EUROPE, MIDDLE EAST & AFRICA PASSIVE IMMUNIZING DRUGS AGAINST RABIES MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
TABLE 126. EUROPE, MIDDLE EAST & AFRICA PASSIVE IMMUNIZING DRUGS AGAINST RABIES MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
TABLE 127. EUROPE, MIDDLE EAST & AFRICA PASSIVE IMMUNIZING DRUGS AGAINST RABIES MARKET SIZE, BY FORMULATION, 2018-2024 (USD MILLION)
TABLE 128. EUROPE, MIDDLE EAST & AFRICA PASSIVE IMMUNIZING DRUGS AGAINST RABIES MARKET SIZE, BY FORMULATION, 2025-2030 (USD MILLION)
TABLE 129. EUROPE, MIDDLE EAST & AFRICA PASSIVE IMMUNIZING DRUGS AGAINST RABIES MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
TABLE 130. EUROPE, MIDDLE EAST & AFRICA PASSIVE IMMUNIZING DRUGS AGAINST RABIES MARKET SIZE, BY APPLICATION, 2025-2030 (USD MILLION)
TABLE 131. EUROPE, MIDDLE EAST & AFRICA PASSIVE IMMUNIZING DRUGS AGAINST RABIES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 132. EUROPE, MIDDLE EAST & AFRICA PASSIVE IMMUNIZING DRUGS AGAINST RABIES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 133. EUROPE, MIDDLE EAST & AFRICA PASSIVE IMMUNIZING DRUGS AGAINST RABIES MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 134. EUROPE, MIDDLE EAST & AFRICA PASSIVE IMMUNIZING DRUGS AGAINST RABIES MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 135. EUROPE, MIDDLE EAST & AFRICA PASSIVE IMMUNIZING DRUGS AGAINST RABIES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 136. EUROPE, MIDDLE EAST & AFRICA PASSIVE IMMUNIZING DRUGS AGAINST RABIES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 137. EUROPE, MIDDLE EAST & AFRICA PASSIVE IMMUNIZING DRUGS AGAINST RABIES MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
TABLE 138. EUROPE, MIDDLE EAST & AFRICA PASSIVE IMMUNIZING DRUGS AGAINST RABIES MARKET SIZE, BY COUNTRY, 2025-2030 (USD MILLION)
TABLE 139. UNITED KINGDOM PASSIVE IMMUNIZING DRUGS AGAINST RABIES MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
TABLE 140. UNITED KINGDOM PASSIVE IMMUNIZING DRUGS AGAINST RABIES MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
TABLE 141. UNITED KINGDOM PASSIVE IMMUNIZING DRUGS AGAINST RABIES MARKET SIZE, BY FORMULATION, 2018-2024 (USD MILLION)
TABLE 142. UNITED KINGDOM PASSIVE IMMUNIZING DRUGS AGAINST RABIES MARKET SIZE, BY FORMULATION, 2025-2030 (USD MILLION)
TABLE 143. UNITED KINGDOM PASSIVE IMMUNIZING DRUGS AGAINST RABIES MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
TABLE 144. UNITED KINGDOM PASSIVE IMMUNIZING DRUGS AGAINST RABIES MARKET SIZE, BY APPLICATION, 2025-2030 (USD MILLION)
TABLE 145. UNITED KINGDOM PASSIVE IMMUNIZING DRUGS AGAINST RABIES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 146. UNITED KINGDOM PASSIVE IMMUNIZING DRUGS AGAINST RABIES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 147. UNITED KINGDOM PASSIVE IMMUNIZING DRUGS AGAINST RABIES MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 148. UNITED KINGDOM PASSIVE IMMUNIZING DRUGS AGAINST RABIES MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 149. UNITED KINGDOM PASSIVE IMMUNIZING DRUGS AGAINST RABIES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 150. UNITED KINGDOM PASSIVE IMMUNIZING DRUGS AGAINST RABIES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 151. GERMANY PASSIVE IMMUNIZING DRUGS AGAINST RABIES MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
TABLE 152. GERMANY PASSIVE IMMUNIZING DRUGS AGAINST RABIES MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
TABLE 153. GERMANY PASSIVE IMMUNIZING DRUGS AGAINST RABIES MARKET SIZE, BY FORMULATION, 2018-2024 (USD MILLION)
TABLE 154. GERMANY PASSIVE IMMUNIZING DRUGS AGAINST RABIES MARKET SIZE, BY FORMULATION, 2025-2030 (USD MILLION)
TABLE 155. GERMANY PASSIVE IMMUNIZING DRUGS AGAINST RABIES MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
TABLE 156. GERMANY PASSIVE IMMUNIZING DRUGS AGAINST RABIES MARKET SIZE, BY APPLICATION, 2025-2030 (USD MILLION)
TABLE 157. GERMANY PASSIVE IMMUNIZING DRUGS AGAINST RABIES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 158. GERMANY PASSIVE IMMUNIZING DRUGS AGAINST RABIES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 159. GERMANY PASSIVE IMMUNIZING DRUGS AGAINST RABIES MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 160. GERMANY PASSIVE IMMUNIZING DRUGS AGAINST RABIES MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 161. GERMANY PASSIVE IMMUNIZING DRUGS AGAINST RABIES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 162. GERMANY PASSIVE IMMUNIZING DRUGS AGAINST RABIES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 163. FRANCE PASSIVE IMMUNIZING DRUGS AGAINST RABIES MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
TABLE 164. FRANCE PASSIVE IMMUNIZING DRUGS AGAINST RABIES MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
TABLE 165. FRANCE PASSIVE IMMUNIZING DRUGS AGAINST RABIES MARKET SIZE, BY FORMULATION, 2018-2024 (USD MILLION)
TABLE 166. FRANCE PASSIVE IMMUNIZING DRUGS AGAINST RABIES MARKET SIZE, BY FORMULATION, 2025-2030 (USD MILLION)
TABLE 167. FRANCE PASSIVE IMMUNIZING DRUGS AGAINST RABIES MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
TABLE 168. FRANCE PASSIVE IMMUNIZING DRUGS AGAINST RABIES MARKET SIZE, BY APPLICATION, 2025-2030 (USD MILLION)
TABLE 169. FRANCE PASSIVE IMMUNIZING DRUGS AGAINST RABIES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 170. FRANCE PASSIVE IMMUNIZING DRUGS AGAINST RABIES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 171. FRANCE PASSIVE IMMUNIZING DRUGS AGAINST RABIES MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 172. FRANCE PASSIVE IMMUNIZING DRUGS AGAINST RABIES MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 173. FRANCE PASSIVE IMMUNIZING DRUGS AGAINST RABIES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 174. FRANCE PASSIVE IMMUNIZING DRUGS AGAINST RABIES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 175. RUSSIA PASSIVE IMMUNIZING DRUGS AGAINST RABIES MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
TABLE 176. RUSSIA PASSIVE IMMUNIZING DRUGS AGAINST RABIES MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
TABLE 177. RUSSIA PASSIVE IMMUNIZING DRUGS AGAINST RABIES MARKET SIZE, BY FORMULATION, 2018-2024 (USD MILLION)
TABLE 178. RUSSIA PASSIVE IMMUNIZING DRUGS AGAINST RABIES MARKET SIZE, BY FORMULATION, 2025-2030 (USD MILLION)
TABLE 179. RUSSIA PASSIVE IMMUNIZING DRUGS AGAINST RABIES MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
TABLE 180. RUSSIA PASSIVE IMMUNIZING DRUGS AGAINST RABIES MARKET SIZE, BY APPLICATION, 2025-2030 (USD MILLION)
TABLE 181. RUSSIA PASSIVE IMMUNIZING DRUGS AGAINST RABIES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 182. RUSSIA PASSIVE IMMUNIZING DRUGS AGAINST RABIES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 183. RUSSIA PASSIVE IMMUNIZING DRUGS AGAINST RABIES MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 184. RUSSIA PASSIVE IMMUNIZING DRUGS AGAINST RABIES MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 185. RUSSIA PASSIVE IMMUNIZING DRUGS AGAINST RABIES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 186. RUSSIA PASSIVE IMMUNIZING DRUGS AGAINST RABIES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 187. ITALY PASSIVE IMMUNIZING DRUGS AGAINST RABIES MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
TABLE 188. ITALY PASSIVE IMMUNIZING DRUGS AGAINST RABIES MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
TABLE 189. ITALY PASSIVE IMMUNIZING DRUGS AGAINST RABIES MARKET SIZE, BY FORMULATION, 2018-2024 (USD MILLION)
TABLE 190. ITALY PASSIVE IMMUNIZING DRUGS AGAINST RABIES MARKET SIZE, BY FORMULATION, 2025-2030 (USD MILLION)
TABLE 191. ITALY PASSIVE IMMUNIZING DRUGS AGAINST RABIES MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
TABLE 192. ITALY PASSIVE IMMUNIZING DRUGS AGAINST RABIES MARKET SIZE, BY APPLICATION, 2025-2030 (USD MILLION)
TABLE 193. ITALY PASSIVE IMMUNIZING DRUGS AGAINST RABIES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 194. ITALY PASSIVE IMMUNIZING DRUGS AGAINST RABIES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 195. ITALY PASSIVE IMMUNIZING DRUGS AGAINST RABIES MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 196. ITALY PASSIVE IMMUNIZING DRUGS AGAINST RABIES MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 197. ITALY PASSIVE IMMUNIZING DRUGS AGAINST RABIES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 198. ITALY PASSIVE IMMUNIZING DRUGS AGAINST RABIES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 199. SPAIN PASSIVE IMMUNIZING DRUGS AGAINST RABIES MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
TABLE 200. SPAIN PASSIVE IMMUNIZING DRUGS AGAINST RABIES MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
TABLE 201. SPAIN PASSIVE IMMUNIZING DRUGS AGAINST RABIES MARKET SIZE, BY FORMULATION, 2018-2024 (USD MILLION)
TABLE 202. SPAIN PASSIVE IMMUNIZING DRUGS AGAINST RABIES MARKET SIZE, BY FORMULATION, 2025-2030 (USD MILLION)
TABLE 203. SPAIN PASSIVE IMMUNIZING DRUGS AGAINST RABIES MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
TABLE 204. SPAIN PASSIVE IMMUNIZING DRUGS AGAINST RABIES MARKET SIZE, BY APPLICATION, 2025-2030 (USD MILLION)
TABLE 205. SPAIN PASSIVE IMMUNIZING DRUGS AGAINST RABIES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 206. SPAIN PASSIVE IMMUNIZING DRUGS AGAINST RABIES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 207. SPAIN PASSIVE IMMUNIZING DRUGS AGAINST RABIES MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 208. SPAIN PASSIVE IMMUNIZING DRUGS AGAINST RABIES MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 209. SPAIN PASSIVE IMMUNIZING DRUGS AGAINST RABIES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 210. SPAIN PASSIVE IMMUNIZING DRUGS AGAINST RABIES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 211. UNITED ARAB EMIRATES PASSIVE IMMUNIZING DRUGS AGAINST RABIES MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
TABLE 212. UNITED ARAB EMIRATES PASSIVE IMMUNIZING DRUGS AGAINST RABIES MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
TABLE 213. UNITED ARAB EMIRATES PASSIVE IMMUNIZING DRUGS AGAINST RABIES MARKET SIZE, BY FORMULATION, 2018-2024 (USD MILLION)
TABLE 214. UNITED ARAB EMIRATES PASSIVE IMMUNIZING DRUGS AGAINST RABIES MARKET SIZE, BY FORMULATION, 2025-2030 (USD MILLION)
TABLE 215. UNITED ARAB EMIRATES PASSIVE IMMUNIZING DRUGS AGAINST RABIES MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
TABLE 216. UNITED ARAB EMIRATES PASSIVE IMMUNIZING DRUGS AGAINST RABIES MARKET SIZE, BY APPLICATION, 2025-2030 (USD MILLION)
TABLE 217. UNITED ARAB EMIRATES PASSIVE IMMUNIZING DRUGS AGAINST RABIES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 218. UNITED ARAB EMIRATES PASSIVE IMMUNIZING DRUGS AGAINST RABIES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 219. UNITED ARAB EMIRATES PASSIVE IMMUNIZING DRUGS AGAINST RABIES MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 220. UNITED ARAB EMIRATES PASSIVE IMMUNIZING DRUGS AGAINST RABIES MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 221. UNITED ARAB EMIRATES PASSIVE IMMUNIZING DRUGS AGAINST RABIES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 222. UNITED ARAB EMIRATES PASSIVE IMMUNIZING DRUGS AGAINST RABIES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 223. SAUDI ARABIA PASSIVE IMMUNIZING DRUGS AGAINST RABIES MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
TABLE 224. SAUDI ARABIA PASSIVE IMMUNIZING DRUGS AGAINST RABIES MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
TABLE 225. SAUDI ARABIA PASSIVE IMMUNIZING DRUGS AGAINST RABIES MARKET SIZE, BY FORMULATION, 2018-2024 (USD MILLION)
TABLE 226. SAUDI ARABIA PASSIVE IMMUNIZING DRUGS AGAINST RABIES MARKET SIZE, BY FORMULATION, 2025-2030 (USD MILLION)
TABLE 227. SAUDI ARABIA PASSIVE IMMUNIZING DRUGS AGAINST RABIES MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
TABLE 228. SAUDI ARABIA PASSIVE IMMUNIZING DRUGS AGAINST RABIES MARKET SIZE, BY APPLICATION, 2025-2030 (USD MILLION)
TABLE 229. SAUDI ARABIA PASSIVE IMMUNIZING DRUGS AGAINST RABIES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 230. SAUDI ARABIA PASSIVE IMMUNIZING DRUGS AGAINST RABIES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 231. SAUDI ARABIA PASSIVE IMMUNIZING DRUGS AGAINST RABIES MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 232. SAUDI ARABIA PASSIVE IMMUNIZING DRUGS AGAINST RABIES MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 233. SAUDI ARABIA PASSIVE IMMUNIZING DRUGS AGAINST RABIES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 234. SAUDI ARABIA PASSIVE IMMUNIZING DRUGS AGAINST RABIES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 235. SOUTH AFRICA PASSIVE IMMUNIZING DRUGS AGAINST RABIES MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
TABLE 236. SOUTH AFRICA PASSIVE IMMUNIZING DRUGS AGAINST RABIES MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
TABLE 237. SOUTH AFRICA PASSIVE IMMUNIZING DRUGS AGAINST RABIES MARKET SIZE, BY FORMULATION, 2018-2024 (USD MILLION)
TABLE 238. SOUTH AFRICA PASSIVE IMMUNIZING DRUGS AGAINST RABIES MARKET SIZE, BY FORMULATION, 2025-2030 (USD MILLION)
TABLE 239. SOUTH AFRICA PASSIVE IMMUNIZING DRUGS AGAINST RABIES MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
TABLE 240. SOUTH AFRICA PASSIVE IMMUNIZING DRUGS AGAINST RABIES MARKET SIZE, BY APPLICATION, 2025-2030 (USD MILLION)
TABLE 241. SOUTH AFRICA PASSIVE IMMUNIZING DRUGS AGAINST RABIES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 242. SOUTH AFRICA PASSIVE IMMUNIZING DRUGS AGAINST RABIES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 243. SOUTH AFRICA PASSIVE IMMUNIZING DRUGS AGAINST RABIES MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 244. SOUTH AFRICA PASSIVE IMMUNIZING DRUGS AGAINST RABIES MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 245. SOUTH AFRICA PASSIVE IMMUNIZING DRUGS AGAINST RABIES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 246. SOUTH AFRICA PASSIVE IMMUNIZING DRUGS AGAINST RABIES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 247. DENMARK PASSIVE IMMUNIZING DRUGS AGAINST RABIES MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
TABLE 248. DENMARK PASSIVE IMMUNIZING DRUGS AGAINST RABIES MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
TABLE 249. DENMARK PASSIVE IMMUNIZING DRUGS AGAINST RABIES MARKET SIZE, BY FORMULATION, 2018-2024 (USD MILLION)
TABLE 250. DENMARK PASSIVE IMMUNIZING DRUGS AGAINST RABIES MARKET SIZE, BY FORMULATION, 2025-2030 (USD MILLION)
TABLE 251. DENMARK PASSIVE IMMUNIZING DRUGS AGAINST RABIES MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
TABLE 252. DENMARK PASSIVE IMMUNIZING DRUGS AGAINST RABIES MARKET SIZE, BY APPLICATION, 2025-2030 (USD MILLION)
TABLE 253. DENMARK PASSIVE IMMUNIZING DRUGS AGAINST RABIES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 254. DENMARK PASSIVE IMMUNIZING DRUGS AGAINST RABIES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 255. DENMARK PASSIVE IMMUNIZING DRUGS AGAINST RABIES MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 256. DENMARK PASSIVE IMMUNIZING DRUGS AGAINST RABIES MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 257. DENMARK PASSIVE IMMUNIZING DRUGS AGAINST RABIES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 258. DENMARK PASSIVE IMMUNIZING DRUGS AGAINST RABIES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 259. NETHERLANDS PASSIVE IMMUNIZING DRUGS AGAINST RABIES MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
TABLE 260. NETHERLANDS PASSIVE IMMUNIZING DRUGS AGAINST RABIES MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
TABLE 261. NETHERLANDS PASSIVE IMMUNIZING DRUGS AGAINST RABIES MARKET SIZE, BY FORMULATION, 2018-2024 (USD MILLION)
TABLE 262. NETHERLANDS PASSIVE IMMUNIZING DRUGS AGAINST RABIES MARKET SIZE, BY FORMULATION, 2025-2030 (USD MILLION)
TABLE 263. NETHERLANDS PASSIVE IMMUNIZING DRUGS AGAINST RABIES MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
TABLE 264. NETHERLANDS PASSIVE IMMUNIZING DRUGS AGAINST RABIES MARKET SIZE, BY APPLICATION, 2025-2030 (USD MILLION)
TABLE 265. NETHERLANDS PASSIVE IMMUNIZING DRUGS AGAINST RABIES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 266. NETHERLANDS PASSIVE IMMUNIZING DRUGS AGAINST RABIES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 267. NETHERLANDS PASSIVE IMMUNIZING DRUGS AGAINST RABIES MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 268. NETHERLANDS PASSIVE IMMUNIZING DRUGS AGAINST RABIES MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 269. NETHERLANDS PASSIVE IMMUNIZING DRUGS AGAINST RABIES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 270. NETHERLANDS PASSIVE IMMUNIZING DRUGS AGAINST RABIES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 271. QATAR PASSIVE IMMUNIZING DRUGS AGAINST RABIES MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
TABLE 272. QATAR PASSIVE IMMUNIZING DRUGS AGAINST RABIES MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
TABLE 273. QATAR PASSIVE IMMUNIZING DRUGS AGAINST RABIES MARKET SIZE, BY FORMULATION, 2018-2024 (USD MILLION)
TABLE 274. QATAR PASSIVE IMMUNIZING DRUGS AGAINST RABIES MARKET SIZE, BY FORMULATION, 2025-2030 (USD MILLION)
TABLE 275. QATAR PASSIVE IMMUNIZING DRUGS AGAINST RABIES MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
TABLE 276. QATAR PASSIVE IMMUNIZING DRUGS AGAINST RABIES MARKET SIZE, BY APPLICATION, 2025-2030 (USD MILLION)
TABLE 277. QATAR PASSIVE IMMUNIZING DRUGS AGAINST RABIES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 278. QATAR PASSIVE IMMUNIZING DRUGS AGAINST RABIES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 279. QATAR PASSIVE IMMUNIZING DRUGS AGAI

Samples

Loading
LOADING...

Companies Mentioned

The companies profiled in this Passive Immunizing Drugs against Rabies Market report include:
  • Grifols S.A.
  • Takeda Pharmaceutical Company Limited
  • CSL Limited
  • Octapharma AG
  • Kedrion S.p.A.
  • Serum Institute of India Private Limited
  • Les Laboratoires Français du Fractionnement et des Biotechnologies (LFB)
  • Shandong Taibang Biopharmaceutical Co., Ltd.
  • Tianjin Kinghem Pharmaceutical Co., Ltd.
  • Haffkine Bio-Pharmaceutical Corporation Limited

Related Topics

Related Reports

Anti-Rabies Serum Market Report 2025 - Product Image

Anti-Rabies Serum Market Report 2025

  • Report
  • 175 Pages
  • Global
From
Human Rabies Treatment Market Size, Market Share, Application Analysis, Regional Outlook, Growth Trends, Key Players, Competitive Strategies and Forecasts, 2022 to 2030 - Product Image

Human Rabies Treatment Market Size, Market Share, Application Analysis, Regional Outlook, Growth Trends, Key Players, Competitive Strategies and Forecasts, 2022 to 2030

  • Report
  • 119 Pages
  • Global
From
Rabies Treatment - Global Strategic Business Report - Product Image

Rabies Treatment - Global Strategic Business Report

  • Report
  • 179 Pages
  • Global
From
Anthrax Treatment - Global Strategic Business Report - Product Image

Anthrax Treatment - Global Strategic Business Report

  • Report
  • 373 Pages
  • Global
From
Rabies Infection Pipeline Analysis Report 2025 - Product Image

Rabies Infection Pipeline Analysis Report 2025

  • Report
  • 200 Pages
  • Global
From
Copyright © 2002-2025 Research and Markets. All Rights Reserved.